A cloud-based, end-to-end electronic chemotherapy prescribing platform

iQemo was designed with patient safety at its core. Built-in features include automatic dose calculations, allergy and sensitivity alerts, toxicity-linked decision support, drug-interaction checks and barcode scanning for both wristbands and medications. Together, these safeguards minimise risk and ensure every patient receives the right treatment at the right time.

Prescribing and administering systemic anticancer therapy is highly complex. iQemo streamlines these workflows through intuitive design, regimen templates and decision support—reducing administrative burden and freeing clinicians to focus on direct patient care.

As a cloud-native solution, iQemo requires no software installation or server maintenance. Clinicians can securely access the platform from almost any internet-connected device, ensuring continuity of care across locations.

iQemo integrates with existing healthcare systems, including PAS, pathology, laboratory and smart infusion pumps, using industry-standard HL7 messaging. This ensures real-time clinical data flows between systems, supporting faster, more informed decision-making.

With complete end-to-end oversight for prescribing, administration, and reporting, iQemo supports compliance with all national systemic anticancer therapy (SACT) reporting requirements. The platform’s reporting capabilities also enable services to monitor trends, analyse outcomes and optimise future planning.

From dynamic drug sets that streamline biosimilar substitution to automated compliance with chemotherapy dose bands, iQemo offers the flexibility healthcare organisations need to adapt to evolving clinical and regulatory requirements.

Hosted in a secure, resilient and compliant environment, iQemo ensures high availability and minimal downtime. Multi-data centre deployment and full redundancy enables organisations to trust the system to perform reliably, even under demanding conditions.